TREATMENTS FOR MDS & SECONDARY AML

Recording from the 2024 International Bone Marrow Failure Scientific Symposium

High Risk:
Yasmin Abaza, MD - Northwestern University
Limited advances in treatments for HR MDS

Jayastu Senapti, MBBS, MD, DM - MD Anderson Cancer Center
Venetoclax and MDS genetics

Mahasweta Gooptu, MD - Dana-Farber Cancer Institute
Who should be transplanted with TP53 MDS?

Zach DeFilipp, MD - Massachusetts General HOSPITAL
Nico Gagelmann, MD - University Medical Center Hamburg-Eppendorf, GERMANY
Shyam Patel, MD, PhD - UMass Chan Medical School
Jacqueline Garcia, MD - Dana-Farber Cancer Institute


Low Risk:

Tian Zhang, MD, PhD - Stanford University
IDH mutant CCUS/MDS

Yazan Madanat, MD - UT Southwestern
Imetelstat in Low Risk MDS

Angela Consagra, MD - University of Florence, Italy
Luspatercept in MDS

Zoey (Zhuoer) Xie, MD, MS - Moffitt Cancer Center
Andrew Brunner, MD - Massachusetts General HOSPITAL

Andrew Brunner, MD - Massachusetts General HOSPITAL
MDS Response Criteria